Hematological Conditions Associated with COVID-19: Pathophysiology, Clinical Manifestations, and Therapeutic Approaches

This review highlights the significant impact of SARS-CoV-2 on the hematological system, revealing complications such as thrombocytopenia, coagulopathy, venous thromboembolism (VTE), and hemolytic anemia, which contribute notably to morbidity and mortality, especially in critically ill patients. The underlying mechanisms involve direct viral effects, inflammation, cytokine storms, and hypercoagulability. The exacerbation of pre-existing hematological malignancies and the common occurrence of lymphopenia further illustrate the complex interaction between COVID-19 and the immune system. The review emphasizes the importance of early recognition and management of hematological complications for clinical practice. It discusses the necessity of monitoring biomarkers like D-dimer and platelet counts, utilizing imaging techniques for detecting thromboembolic events, and employing timely interventions with anticoagulants and immunomodulators. Tailoring treatment to individual patient needs and involving a multidisciplinary team are essential for improving outcomes, particularly in critically ill patients. The review also focuses on the need for ongoing research to understand the precise mechanisms of these complications, explore genetic and environmental factors, and assess the long-term outcomes of affected patients. It examines the impact of emerging SARS-CoV-2 variants and the importance of developing innovative therapeutic approaches, including personalized medicine and advanced therapies, to address the ongoing challenges in medical practice.